/investors/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_b4e6ff6ef47dceb9694bce8228582222/opko/files/theme/images/logo-sm.png /investors Equisolve Investor Relations Suite /investors/news-events/press-releases/detail/502/opko-health-announces-100-million-share-repurchase-program Thu, 18 Jul 24 08:00:00 -0400 /investors/news-events/press-releases/detail/502/opko-health-announces-100-million-share-repurchase-program /investors/news-events/press-releases/detail/501/opko-health-and-healthcare-royalty-enter-into-250-million-note-purchase-agreement-secured-by-ngenlas-profit-share-payments Wed, 17 Jul 24 16:14:00 -0400 /investors/news-events/press-releases/detail/501/opko-health-and-healthcare-royalty-enter-into-250-million-note-purchase-agreement-secured-by-ngenlas-profit-share-payments /investors/news-events/press-releases/detail/500/opko-health-to-participate-in-the-jefferies-global-healthcare-conference Fri, 31 May 24 10:48:00 -0400 /investors/news-events/press-releases/detail/500/opko-health-to-participate-in-the-jefferies-global-healthcare-conference /investors/news-events/press-releases/detail/499/opko-health-reports-first-quarter-2024-business-highlights-and-financial-results Tue, 07 May 24 16:05:00 -0400 /investors/news-events/press-releases/detail/499/opko-health-reports-first-quarter-2024-business-highlights-and-financial-results /investors/news-events/press-releases/detail/498/opko-health-to-report-first-quarter-2024-financial-results-on-may-7-2024 Fri, 03 May 24 08:00:00 -0400 /investors/news-events/press-releases/detail/498/opko-health-to-report-first-quarter-2024-financial-results-on-may-7-2024 /investors/news-events/press-releases/detail/497/labcorp-announces-acquisition-of-select-assets-of-bioreference-healths-diagnostics-business Thu, 28 Mar 24 08:55:00 -0400 /investors/news-events/press-releases/detail/497/labcorp-announces-acquisition-of-select-assets-of-bioreference-healths-diagnostics-business /investors/news-events/press-releases/detail/496/aids-clinical-trial-group-presents-results-from-phase-1-study-of-modex-trispecific-antibody-for-the-treatment-and-prevention-of-hiv Tue, 05 Mar 24 08:52:00 -0500 /investors/news-events/press-releases/detail/496/aids-clinical-trial-group-presents-results-from-phase-1-study-of-modex-trispecific-antibody-for-the-treatment-and-prevention-of-hiv /investors/news-events/press-releases/detail/495/opko-health-reports-fourth-quarter-2023-business-highlights-and-financial-results Tue, 27 Feb 24 16:05:00 -0500 /investors/news-events/press-releases/detail/495/opko-health-reports-fourth-quarter-2023-business-highlights-and-financial-results /investors/news-events/press-releases/detail/494/opko-health-to-report-fourth-quarter-2023-financial-results-on-february-27-2024 Thu, 22 Feb 24 16:05:00 -0500 /investors/news-events/press-releases/detail/494/opko-health-to-report-fourth-quarter-2023-financial-results-on-february-27-2024 /investors/news-events/press-releases/detail/493/opko-health-announces-closing-of-private-offering-of-230-million-convertible-senior-notes-due-2029-including-full-exercise-of-initial-purchasers-option-to-purchase-additional-notes Tue, 09 Jan 24 16:05:00 -0500 /investors/news-events/press-releases/detail/493/opko-health-announces-closing-of-private-offering-of-230-million-convertible-senior-notes-due-2029-including-full-exercise-of-initial-purchasers-option-to-purchase-additional-notes